Genocea Boosted By Biotech's Recent Rise After 12-Month Herpes Data Update
This article was originally published in Scrip
Executive Summary
Genocea Biosciences Inc. is holding out hope that Phase II data from genital herpes patients treated with GEN-003 for 12 months will give the therapeutic vaccine a market advantage, and while the commercial potential is unclear given the mixed data the company reported on March 31, its stock price soared on the clinical trial update for its sole clinical drug candidate.
You may also be interested in...
Finance Watch: Genocea, Mateon Shift Strategies, Cut Jobs To Preserve Cash
Genocea shifts to preclinical neoantigen-based cancer vaccines rather than advance a Phase III-ready herpes program on its own and Mateon gives up on its lead drug as placebo outperforms. Also, Juno tops recent public company financings and new VC funds back early-stage firms.
Genital Herpes: New Therapeutic Approaches Advance
New vaccines and a compound with new mechanism of action that are in early clinical trials suggest the poorly served antiherpes market could be rejuvenated in the next few years.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.